Mesenchymal stem cell therapy - Genesis
Alternative Names: Allogeneic human umbilical cord tissue-derived mesenchymal stem cellsLatest Information Update: 31 Oct 2021
Price :
$50 *
At a glance
- Originator Genesis
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 20 Mar 2019 Discontinued - Phase-I/II for Multiple sclerosis (Recurrent) in Trinidad and Tobago (IV)
- 03 Nov 2015 Genesis terminates a phase I/II trial in Multiple sclerosis in Trinidad and Tobago due to lack of funds (NCT02418325)
- 01 Feb 2015 Phase-I/II clinical trials in Multiple sclerosis (Recurrent) in Trinidad and Tobago (IV)